France-based PEP-Therapy has raised €1.3M in initial funding. This sum, invested by the Quadrivium 1 seed fund and a business angel, Dr Bernard Majoie, will enable the cancer-focused company to undertake regulatory development of its first therapeutic product, a biomarker.

The biomarker works as a predictive for foreseeing the effectiveness of a cancer treatment. The product relies on the innovative technology of bi-functional peptides, which penetrate cells and then specifically block pathological mechanisms, without affecting normal physiological mechanisms.

Source: PEP-Therapy

Source: PEP-Therapy

ADVERTISEMENT

These funds were provided by the Quadrivium 1 seed fund, managed by Seventure Partners, for €1M, supplemented by a personal investment of €300k from Dr. Bernard Majoie, former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l’Innovation (FFMI).

Antoine Prestat

Antoine Prestat

Antoine Prestat, CEO of PEP-Therapy, welcomed this important new phase in the company’s development. “This funding will allow us to carry out regulatory toxicity studies, the final phase before clinical trials. PEP-Therapy’s product has an additional competitive advantage: it is combined with predictive biomarkers which will help identify patients likely to respond to treatment. This fits well with the experience in companion diagnostics gained by FFMI, and meets a currently increasing demand for personalised medicine”.

PEP-Therapy has a portfolio of targeted therapies based on the same innovative approach: a cell-penetrating and interfering peptide (CP&IP) technology developed at Université Pierre et Marie Curie, Inserm and Institut Curie, Paris.

With this financial support, PEP-Therapy is taking a new step forward, giving itself the resources required to scale up the promising development of its targeted treatments,” welcomed Antoine Prestat.

Previous post

Will 2015 be the year of biosimilars?

Next post

Giant Baupost Group bets on Biotie

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.